zoledronic acid has been researched along with Rhabdomyosarcoma, Alveolar in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujiwara, K; Ishida, H; Kanamitsu, K; Shimada, A; Tsukahara, H; Washio, K | 1 |
1 other study(ies) available for zoledronic acid and Rhabdomyosarcoma, Alveolar
| Article | Year |
|---|---|
A case of alveolar rhabdomyosarcoma showing concurrent responsive bone marrow lesions and refractory pancreatic lesions to pazopanib monotherapy.
Topics: Adolescent; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Neoplasms; Fluorodeoxyglucose F18; Forkhead Box Protein O1; Humans; Indazoles; Oncogene Proteins, Fusion; Paired Box Transcription Factors; Pancreatic Neoplasms; PAX3 Transcription Factor; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Rhabdomyosarcoma, Alveolar; Sulfonamides; Tumor Microenvironment; Zoledronic Acid | 2020 |